Head-to-head evidence
Furosemide (subcutaneous, scPharmaceuticals) vs Torsemide (Soaanz)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: NKCC2 · full Heart Failure pipeline
Furosemide (subcutaneous, scPharmaceuticals) · FUROSCIX
Marketed by scPharmaceuticals and partners
NCT03458325 · Phase 3 · completed
This was a small, open-label, nonrandomized single-group study: 25 participants received Furoscix, with comparison made against propensity-matched historical claims controls rather than a concurrently randomized control group. The primary endpoint was 30-day healthcare utilization cost, a surrogate economic measure, and the reported comparison favored Furoscix with p<0.0001, but the limited design and sample size reduce confidence in the finding.
Next expected readout: November 2026 · NCT07008365 (registry estimate)
Torsemide (Soaanz)
Marketed by Sarfez Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Furosemide (subcutaneous, scPharmaceuticals)'s landscape · Torsemide (Soaanz)'s landscape